We are live on ! Find out more
SGMO

SANGAMO THERAPEUTICS INC

Delisted

SGMO was delisted on the 4th of May, 2026.

111 hedge funds and large institutions have $408M invested in SANGAMO THERAPEUTICS INC in 2013 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 40 increasing their positions, 26 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,513% more call options, than puts

Call options by funds: $82.4M | Put options by funds: $5.11M

144% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 9

70% more capital invested

Capital invested by funds: $240M → $408M (+$168M)

54% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 26

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

12% more funds holding

Funds holding: 99111 (+12)

Holders
111
Holders Change
+12
Holders Change %
+12.12%
% of All Funds
3.6%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.1%
New
22
Increased
40
Reduced
26
Closed
9
Calls
$82.4M
Puts
$5.11M
Net Calls
+$77.3M
Net Calls Change
+$19.7M
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$44.7M -$11M -1,109,850 -21%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$39.1M +$16.7M +1,685,000 +82%
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$39.1M +$23.1M +2,327,800 +166%
WA
4
Wasatch Advisors
Utah
$31.8M -$709K -71,424 -2%
BFA
5
BlackRock Fund Advisors
California
$24.2M +$4.64M +467,028 +25%
State Street
6
State Street
Massachusetts
$22.6M -$5.57M -561,229 -21%
BIT
7
BlackRock Institutional Trust
California
$18.2M +$851K +85,726 +5%
AWMDMG
8
Austin W. Marxe & David M. Greenhouse
New York
$18M -$438K -44,102 -3%
Vanguard Group
9
Vanguard Group
Pennsylvania
$17.5M +$2.59M +260,599 +18%
Jennison Associates
10
Jennison Associates
New York
$15.6M +$14.8M +1,486,498 New
Goldman Sachs
11
Goldman Sachs
New York
$13.9M +$10.9M +1,094,175 +473%
PA
12
Perceptive Advisors
New York
$10.1M +$9.58M +965,000 New
First Eagle Investment Management
13
First Eagle Investment Management
New York
$8.88M +$4.2M +423,200 +100%
Northern Trust
14
Northern Trust
Illinois
$8.71M +$108K +10,919 +1%
Invesco
15
Invesco
Georgia
$7.3M +$6.9M +694,750 +78,238%
FC
16
FIC Capital
New York
$7.09M -$5.53K -557 -0.1%
TAM
17
Tiverton Asset Management
Delaware
$6.37M
Morgan Stanley
18
Morgan Stanley
New York
$4.22M -$1.95M -196,462 -33%
Allianz Asset Management
19
Allianz Asset Management
Germany
$3.63M +$241K +24,257 +8%
WSA
20
Wall Street Associates
California
$3.45M +$3.27M +329,075 New
TCIM
21
TIAA CREF Investment Management
New York
$3.21M -$74.5K -7,503 -2%
Bank of America
22
Bank of America
North Carolina
$3.06M -$629K -63,339 -18%
Deutsche Bank
23
Deutsche Bank
Germany
$2.94M +$515K +51,888 +23%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$2.94M +$187K +18,853 +7%
PC
25
PointState Capital
New York
$2.91M +$2.75M +277,300 New

SGMO Hedge Fund Activity: Q3 2013 in Review

111 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q3 2013, worth a combined $408M — up 70% from $240M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new SGMO positions and 9 closed out — a net gain of 13 holders — while 40 added to existing stakes and 26 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $23.1M. The largest seller was RA Capital Management, cutting an estimated $11M.

  • 111 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q3 2013, up from 99 in Q2 2013.
  • Funds reported $408M of SANGAMO THERAPEUTICS INC stock for Q3 2013, up 70% quarter-over-quarter.
  • 22 funds opened new SANGAMO THERAPEUTICS INC positions in Q3 2013 and 9 closed out, a net change of +13 holders.
  • The largest SANGAMO THERAPEUTICS INC buyer in Q3 2013 was Adage Capital Partners, an estimated $23.1M added.
  • The largest SANGAMO THERAPEUTICS INC seller in Q3 2013 was RA Capital Management, an estimated $11M sold.

Based on aggregated 13F filings for Q3 2013.